Market cap
$0 Mln
Recently Viewed
Clear All$0.00
$0.00 (0.00%)As on 04-May-2026 16:00EDT
Market cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-5.8 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.2
Debt to Equity
--
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
42,622,559
CFO
$-292.57 Mln
EBITDA
$-342.55 Mln
Net Profit
$-357.07 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kaleido Biosciences (KLDO)
| -- | -- | -- | -- | -20.6 | -89.4 | -- |
|
BSE Sensex*
| -9.0 | 5.0 | -8.1 | -4.3 | 7.6 | 9.8 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
|---|---|---|
|
Kaleido Biosciences (KLDO)
| -73.7 | 81.3 |
|
S&P Small-Cap 600
| 25.3 | 9.6 |
|
BSE Sensex
| 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kaleido Biosciences (KLDO)
|
0.0 | 0.0 | 0.0 | 0.0 | -- | -- | -- | 0.0 |
| 76.9 | 10,475.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 46.8 | 18.4 | |
| 45.1 | 11,095.1 | 2,320.1 | 782.6 | 39.0 | 35.5 | 15.7 | 5.1 | |
| 89.3 | 11,613.4 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.5 | 7,577.6 | 1,396.6 | 316.9 | 59.8 | 153.6 | 25 | 155.2 | |
| 294.4 | 7,831.1 | 389.1 | 204.8 | 41.5 | 18.9 | 38.9 | 6.4 | |
| 510.5 | 11,844.1 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.7 | |
| 421.3 | 11,924.8 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.2 | 19.9 | |
| 102.1 | 7,822.0 | 0.0 | -425.4 | -- | -36.7 | -- | 6.3 | |
| 332.7 | 9,029.2 | 0.0 | -303.3 | -- | -45.8 | -- | 10.3 |
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of... hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic immune disease, chronic obstructive pulmonary disease pathogens, and immuno-oncology. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Read more
Senior Vice President of Technical Operations
Ms. Kimberly Hocknell
Senior Vice President of Technical Operations
Ms. Kimberly Hocknell
Headquarters
Lexington, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Kaleido Biosciences Inc (KLDO) is $0.00 (NASDAQ) as of 04-May-2026 16:00 EDT. Kaleido Biosciences Inc (KLDO) has given a return of -20.63% in the last 3 years.
Since, TTM earnings of Kaleido Biosciences Inc (KLDO) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
-1.13
|
9.60
|
|
2020
|
-4.10
|
15.98
|
|
2019
|
-1.78
|
3.10
|
|
2018
|
--
|
--
|
The 52-week high and low of Kaleido Biosciences Inc (KLDO) are Rs 0.00 and Rs 0.00 as of 05-May-2026.
Kaleido Biosciences Inc (KLDO) has a market capitalisation of $ 0 Mln as on 01-May-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Kaleido Biosciences Inc (KLDO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.